Coverage in The Australian

Interesting commentary by Rebecca Urban in The Australian this morning. A big thank you to the hundreds of people from the Australian biosciences industry who reached out in personal support over the past few weeks. I actually wish Chris Roberts every success. Notwithstanding my views on the product, if anyone should be able to fix the company’s corporate governance,…

Oncosil Clarification and Apology

Life is tough as a public company. Commenting on ASX bioscience companies can sometimes also be tough. This week I received a “shot across the bow” from Oncosil’s (ASX : OSL) lawyers in relation to my posts on the company (communication here, with some names/contact details obfuscated for privacy/courtesy purposes, including my own). I note that I…

Happy New Year – 2016

It’s been an interesting year. When I started this site I really didn’t know what was going to happen… in most respects, it has exceeded my expectations. A Few Opening Remarks On a positive note, I genuinely felt support for the mission of trying to create a fresh dialogue around the quality and transparency of ASX-listed companies operating in this…

OSL : Follow-up

Since my last post on OSL (ASX : OSL), I’ve had a few interesting reach-outs confirming my viewpoint on this company and also providing a bit more “colour”. I should note that all of this information is actually reasonably consistent with the discussion I had with Daniel Kenny (CEO) last week, with one exception and I…

The 2000 Mile Rule

When I was a kid, my Dad and I drove across the Nullarbor Plain, from Adelaide to Perth. I will never forget the experience and it rests in my mind as one of the most visually spectacular stretches of road I have ever driven along. It also very much reinforced my perception of how remote and far-flung…